Ketek
(telithromycin)ApprovedSmall molecule
SanofiTelithromycin is an antibiotic used to treat bacterial infections, particularly respiratory tract infections like community-acquired pneumonia and bronchitis.[2] Ketek is currently approved and in use across 10 indications[4].[1]
Ketek is one of 147 small molecule programs targeting Bacterial Pneumonia. It is currently in Approved.
10
Indications
22
Total Trials
0
Active Trials
146
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
155 competitors in Pneumonia
#DrugCompanyPhaseTrials
1Ketek
SanofiApproved
Jakafi
IncytePreclinical
Primaquine
SanofiPreclinical
Acanya
PfizerPreclinical
Prevacid
TakedaPreclinical
Plaquenil
Jazz PharmaceuticalsPreclinical
Innohep
Jazz PharmaceuticalsPreclinical
Avlosulfon
AAlmirall, S.A.
Preclinical
Virazole
CConrado Roberto Hoffmann Filho
Preclinical
Advil
KKenvue Brands
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Pneumonia3 trials
Chronic Bronchitis3 trials
Respiratory tract infection3 trials
Sinusitis2 trials
9 more indications
Scrub Typhus1 trial
Efficacy and Safety1 trial
Acute otitis media1 trial
Acceptability1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Feb 9, 2005
KETEK
NDA NDA021144
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ketek drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for telithromycin. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]